[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659402":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":19,"studyPopulation":19,"armGroups":39,"interventions":51,"overallOfficials":19,"centralContacts":19,"locations":19,"responsibleParty":61,"collaborators":19,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":19,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":19,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":19,"overallStatus":83,"whyStopped":19,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":19},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":19},[9,13],{"measure":10,"description":11,"timeFrame":12},"18-month Progression-Free Survival (PFS) rate in phase II","18-month PFS rate is defined as the proportion of participants who are alive and progression free at 18 months from start of study treatment. Assessed according to RECIST v1.1 by investigator.","From enrollment to 18 months after enrollment",{"measure":14,"description":15,"timeFrame":12},"safety in phase Ib","Determine frequency and severity of adverse events as assessed by NCI-CTCAE v5.0",[17,20,22,24,26,28,31],{"measure":18,"description":19,"timeFrame":12},"R0\u002FR1 resection rate",null,{"measure":21,"description":19,"timeFrame":12},"Objective Response Rate (ORR)",{"measure":23,"description":19,"timeFrame":12},"Progression-Free Survival (PFS)",{"measure":25,"description":19,"timeFrame":12},"Time to Response (TTR)",{"measure":27,"description":19,"timeFrame":12},"Disease Control Rate (DCR)",{"measure":29,"description":19,"timeFrame":30},"18-Month\u002F24-Month No Evidence of Disease (NED) Rate","From enrollment to 24 months after enrollment",{"measure":32,"description":19,"timeFrame":30},"Adverse Event",{"allocation":34,"interventionModel":35,"interventionModelDescription":19,"primaryPurpose":36,"observationalModel":19,"timePerspective":19,"maskingInfo":37},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":38,"maskingDescription":19,"whoMasked":19},"NONE",[40,46],{"label":41,"type":42,"description":43,"interventionNames":44},"Arm A ( QL1706 Combined with mFOLFOX6 and Cetuximab )","EXPERIMENTAL","Participants with primary tumors located in the left colorectum and RAS and BRAF wild-type will receive QL1706 Combined with mFOLFOX6 and Cetuximab",[45],"Drug: Arm A",{"label":47,"type":42,"description":48,"interventionNames":49},"Arm B ( QL1706 Combined with FOLFOXIRI and Bevacizumab )","Participants with primary tumors located in the right colorectum and\u002For RAS or BRAF mutant will receive QL1706 Combined with FOLFOXIRI and Bevacizumab",[50],"Drug: Arm B",[52,57],{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":19},"DRUG","Arm A","QL1706 3mg\u002Fkg, IV, D1, Q2W, for a maximum of 2 years.\n\nmFOLFOX6 : Oxaliplatin 85 mg\u002Fm², IV, D1, Q2W, for a maximum of 12 cycles. LV 400mg\u002Fm², IV, D1, Q2W, for a maximum of 2 years. 5-FU 400mg\u002Fm², IV, D1; followed by a continuous intravenous infusion of 1200mg\u002F(m²•d) for 2 days (total dose 2400mg\u002Fm², infusion duration 46-48 hours), Q2W, for a maximum of 2 years.\n\nCetuximab 500mg\u002Fm², IV, D1, Q2W, for a maximum of 2 years.",[41],{"type":53,"name":58,"description":59,"armGroupLabels":60,"otherNames":19},"Arm B","QL1706 3mg\u002Fkg, IV, D1, Q2W, for a maximum of 2 years\n\nFOLFOXIRI :\n\nIrinotecan 150mg\u002Fm², IV, D1, Q2W, for a maximum of 12 cycles Oxaliplatin 85mg\u002Fm², IV, D1, Q2W, for a maximum of 12 cycles LV 400mg\u002Fm², IV, D1, Q2W, for a maximum of 2 years 5-FU (total dose: 2400mg\u002Fm²) via continuous intravenous infusion for 48 hours, D1, Q2W, for a maximum of 2 years\n\nBevacizumab 5mg\u002Fkg, IV, D1, Q2W, for a maximum of 2 years",[47],{"type":62,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100659402","phase-1-the-ql1706-combined-with-chemotherapy-and-either-cetuximab-or-bevacizumab-in-potentially-resectable-colorectal-cancer-patients-with-liver-metastases-100659402",false,"NCT07863869","The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases","A Phase ⅠB\u002FⅡ Study of QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases","Inclusion Criteria:\n\n* Has signed a written informed consent form and voluntarily participates in this study;\n* Age: 18-75 years old, regardless of gender;\n* Histologically or cytologically confirmed colorectal adenocarcinoma with liver metastases, initially unresectable but potentially resectable as assessed by a multidisciplinary team (MDT), without other definite extrahepatic distant metastases;\n* No prior systemic treatment;\n* Known RAS and BRAF status;\n* No contraindications to liver surgery;\n* At least one measurable lesion according to RECIST 1.1;\n* ECOG performance status: 0-1;\n* Expected survival time \\> 12 weeks;\n* Sufficient organ and bone marrow function.\n\nExclusion Criteria:\n\n* Active autoimmune diseases requiring systemic treatment occurring within 2 years before enrollment.\n* Previous receipt of immune checkpoint inhibitors, including: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, etc.\n* Previous receipt of targeted drugs targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or their receptors (VEGFR), including bevacizumab, cetuximab, panitumumab, aflibercept, regorafenib, anlotinib, etc.\n* Definite extrahepatic distant metastatic lesions.\n* Unresectable primary tumor.\n* HIV infection, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation (except corneal transplantation).\n* Previous or concurrent other malignant tumors within 5 years;\n* Accompanying pleural effusion, pericardial effusion, or ascites that is uncontrollable and requires drainage.\n* Known active pulmonary tuberculosis, radiation pneumonitis, drug-induced pneumonia, or other diseases, symptoms, or signs causing severe impairment of lung function.","ALL","18 Years","75 Years",{"count":74,"type":75},102,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE1","PHASE2","The goal of this clinical trial is to learn if QL1706 (Iparomlimab\u002F Tuvonralimab)+ chemotherapy+ cetuximab\u002Fbevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults. It will also learn about the safety of this therapeutic regimen. The main questions it aims to answer are: Does QL1706+ Chemotherapy+ Cetuximab\u002FBevacizumab improve the 18-month progression free survival (PFS) rate of participants?\n\nThe study plans to enroll 90-102 patients, who will be divided into 2 arms based on the primary tumor location and genetic status.\n\nArm A: Patients with primary tumors located in the left colorectum and RAS ( Rat Sarcoma Virus ) and BRAF ( V-raf Murine Sarcoma Viral Oncogene Homolog B ) wild-type.\n\nArm B: Patients with primary tumors located in the right colorectum and\u002For RAS or BRAF mutant\n\nThe study consists of two phases: phase Ib ( safety run-in phase ) and phase II.",[82],"Colorectal Cancer Metastatic to Liver","NOT_YET_RECRUITING","2026-10-04",{"date":86,"type":87},"2026-10-07","ACTUAL",{"date":89,"type":75},"2026-09",{"date":91,"type":75},"2029-11-27",{"name":5,"class":6}]